Thiogenesis Gains DTC Eligibility and Expands U.S. Presence

Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.

Thiogenesis Therapeutics has achieved DTC eligibility in the U.S., facilitating electronic settlement of its shares and aligning with plans for a U.S. listing. The company is also expanding investor relations by participating in the CEM conference and has added $260,900 to its treasury from the exercise of Finder’s Options.

For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.